Ibrutinib Patent Expiration
Ibrutinib is used for treating various types of leukemias, lymphomas, and graft-versus-host disease, including those with specific genetic deletions. It was first introduced by Pharmacyclics Llc
Ibrutinib Patents
Given below is the list of patents protecting Ibrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Imbruvica | US12201690 | Formulations/compositions comprising ibrutinib | Jun 14, 2039 | Pharmacyclics Llc |
| Imbruvica |
US10010507 (Pediatric) | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US10213386 (Pediatric) | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US10828259 (Pediatric) | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US9655857 (Pediatric) | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Sep 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US12364698 | Compositions Containing Ibrutinib | Apr 06, 2036 | Pharmacyclics Llc |
| Imbruvica | US10010507 | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US10213386 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US10828259 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US12551448 | Pharmaceutical Formulations Of A Bruton'S Tyrosine Kinase Inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica | US9655857 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Mar 03, 2036 | Pharmacyclics Llc |
| Imbruvica |
US10463668 (Pediatric) | Methods of treating and preventing graft versus host disease | Apr 24, 2035 | Pharmacyclics Llc |
| Imbruvica |
US10695350 (Pediatric) | Methods of treating and preventing graft versus host disease | Apr 24, 2035 | Pharmacyclics Llc |
| Imbruvica |
US9795604 (Pediatric) | Methods of treating and preventing graft versus host disease | Apr 24, 2035 | Pharmacyclics Llc |
| Imbruvica | US10463668 | Methods of treating and preventing graft versus host disease | Oct 24, 2034 | Pharmacyclics Llc |
| Imbruvica | US10695350 | Methods of treating and preventing graft versus host disease | Oct 24, 2034 | Pharmacyclics Llc |
| Imbruvica | US9795604 | Methods of treating and preventing graft versus host disease | Oct 24, 2034 | Pharmacyclics Llc |
| Imbruvica |
US9296753 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Apr 30, 2034 | Pharmacyclics Llc |
| Imbruvica |
US9540382 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Feb 18, 2034 | Pharmacyclics Llc |
| Imbruvica |
US10106548 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10125140 (Pediatric) | Crystalline forms of a bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10294231 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10294232 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10752634 (Pediatric) | Crystalline forms of a brutons tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10961251 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US9713617 (Pediatric) | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US9725455 (Pediatric) | Crystalline forms of a bruton's tyrosine kinase inhibitor | Dec 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US9296753 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Oct 30, 2033 | Pharmacyclics Llc |
| Imbruvica | US9540382 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Aug 18, 2033 | Pharmacyclics Llc |
| Imbruvica | US10106548 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10125140 | Crystalline forms of a bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10294231 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10294232 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10752634 | Crystalline forms of a brutons tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US10961251 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US9713617 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica | US9725455 | Crystalline forms of a bruton's tyrosine kinase inhibitor | Jun 03, 2033 | Pharmacyclics Llc |
| Imbruvica |
US10004746 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10016435 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10478439 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10653696 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (BTK) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US10751342 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US8754090 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US8999999 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9125889 (Pediatric) | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9801881 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (BTK) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9801883 (Pediatric) | Use of inhibitors of bruton's tyrosine kinase (Btk) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US9814721 (Pediatric) | Use of inhibitors of bruton'S tyrosine kinase (BTK) | Dec 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10004746 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10016435 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10478439 | Use of inhibitors of bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10653696 | Use of inhibitors of bruton's tyrosine kinase (BTK) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US10751342 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US11672803 | Use of inhibitors of Brutons tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US8754090 | Use of inhibitors of bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US8999999 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9125889 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9801881 | Use of inhibitors of bruton's tyrosine kinase (BTK) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9801883 | Use of inhibitors of bruton's tyrosine kinase (Btk) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica | US9814721 | Use of inhibitors of bruton'S tyrosine kinase (BTK) | Jun 03, 2031 | Pharmacyclics Llc |
| Imbruvica |
US8008309 (Pediatric) | Inhibitors of bruton's tyrosine kinase | May 13, 2028 | Pharmacyclics Llc |
| Imbruvica | US8008309 | Inhibitors of bruton's tyrosine kinase | Nov 13, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8563563 (Pediatric) | Inhibitors of bruton's tyrosine kinase | Oct 26, 2027 | Pharmacyclics Llc |
| Imbruvica |
US7514444 (Pediatric) | Inhibitors of bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8476284 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8497277 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8697711 (Pediatric) | Inhibitors of bruton'S tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8703780 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8735403 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8754091 (Pediatric) | Inhibitors of bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8952015 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US8957079 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica |
US9181257 (Pediatric) | Inhibitors of Bruton's tyrosine kinase | Jun 28, 2027 | Pharmacyclics Llc |
| Imbruvica | US8563563 | Inhibitors of bruton's tyrosine kinase | Apr 26, 2027 | Pharmacyclics Llc |
| Imbruvica | US7514444 | Inhibitors of bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8476284 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8497277 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8697711 | Inhibitors of bruton'S tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8703780 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8735403 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8754091 | Inhibitors of bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8952015 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US8957079 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
| Imbruvica | US9181257 | Inhibitors of Bruton's tyrosine kinase | Dec 28, 2026 | Pharmacyclics Llc |
Ibrutinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Ibrutinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
